Citi analyst Liav Abraham upgraded Mylan (MYL) to Buy and raised her price target for the shares to $42 from $36.

The company is best positioned to execute in a challenging operating environment for generics, Abraham tells investors in a research note. Mylan has a "differentiated and durable" generics product portfolio, "broad pipeline" of complex generics/ biosimilars and a more favorable balance sheet profile relative to peers, the analyst contends.

She has Neutral ratings on Teva (TEVA) and Endo (ENDP).